



## Drug Utilization and Evaluation Committee Board Report

The following report pertains to the DUEC meeting at 1:00 p.m. on Monday, January 10<sup>th</sup>, with Dr. Hank Simmons presiding.

### I. Old Business

#### A. Second Review of Drugs: Dr. Jill Johnson, UAMS

Brand	Generic	Use	Recommendation	Rationale
Calquence	acalabrutinib	Leukemia	Cover with prior authorization	New data confirming clinical benefit vs. alternatives
Auvi-Q	epinephrine auto injector	Severe allergic reactions	Cover for children under 33lbs	No alternatives currently available
Valtoco	diazepam nasal spray	Acute treatment of seizures	Cover with prior authorization	New data confirming clinical benefit
Durezol	difluprednate eye drops	Uveitis/Eye inflammation	Cover	New data confirming clinical benefit vs. alternatives
Myrbetriq Suspension	mirabegron	Neurogenic detrusor overactivity	Cover	Add as an alternative for children < 7yr

**\*The DUEC voted to adopt the recommendations as presented.**

## II. New Business

### A. New Drugs: by Dr. Jill Johnson, UAMS

Brand	Generic	Use	Recommendation	Rationale
<b>Non-Specialty Drugs</b>				
<b>Qulipta</b>	atogepant	Migraines	Exclude	No clinical benefit over lower cost plan alternatives
<b>Semglee (YFGN)</b>	insulin glargine (YFGN)	Diabetes	Exclude	Lower cost generic available; see next drug
<b>Insulin glargine (YFGN)</b>	insulin glargine (YFGN)	Diabetes	Cover	Lower cost option vs. alternatives
<b>Tyrvaya</b>	varenicline tartrate	Dry eye disease	Exclude	No clinical benefit over lower cost plan alternatives
<b>Specialty Drugs</b>				
<b>Livmarli</b>	maralixibat chloride	Cholestatic pruritis	Exclude	Lacks meaningful clinical endpoint data
<b>Skytrofa</b>	lonapegsomatropin-TCGD	Growth hormone deficiency	Exclude	No clinical benefit over lower cost plan alternatives
<b>Tavneos</b>	avacopan	ANCA associated vasculitis	Cover with prior authorization	Data supports clinical benefit over plan alternatives
<b>Scemblix</b>	asciminib hydrochloride	Chronic myeloid leukemia	Cover with prior authorization	Data supports clinical benefit over plan alternatives
<b>Voxzogo</b>	vosoritide	Increase growth in children with achondroplasia	Exclude	Lacks meaningful clinical endpoint data
<b>Besremi</b>	ropeginterferon alfa-2B-NJFT	Polycythemia vera	Exclude	No clinical benefit over lower cost plan alternatives

**\*The DUEC voted to adopt the recommendations as presented.**

Respectfully submitted,

Henry F. Simmons, Jr., MD  
Chair, DUEC